Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C3H7NO2S |
Molecular Weight | 121.158 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CS)C(O)=O
InChI
InChIKey=XUJNEKJLAYXESH-REOHCLBHSA-N
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003545
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003545
Cysteine (cysteine hydrochloride is a salt) is a thiol-containing amino acid that is oxidized to form cystine. Cysteine is synthesized from methionine via the trans-sulfuration pathway in the adult, but newborn infants lack the enzyme, cystathionase, necessary to effect this conversion. Therefore, cysteine is generally considered to be an essential amino acid in infants.
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CYSTEINE HYDROCHLORIDE Approved UseCysteine Hydrochloride Injection, USP 0.5 gram is indicated for use only after dilution as an additive to Aminosyn (a crystalline amino acid solution) to meet the intravenous amino acid nutritional requirements of infants receiving total parenteral nutrition. Launch Date5.30236801E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
121 mg/kg 1 times / day multiple, intravenous (total daily dose) Highest studied dose Dose: 121 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 121 mg/kg, 1 times / day Sources: |
unhealthy, 34±6 weeks n = 6 Health Status: unhealthy Condition: Parenteral nutrition Age Group: 34±6 weeks Sex: M+F Population Size: 6 Sources: |
|
22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Disc. AE: Embolism pulmonary, Vein disorder NOS... AEs leading to discontinuation/dose reduction: Embolism pulmonary Sources: Page: p.1Vein disorder NOS Thrombosis Blood urea nitrogen increased Acid base balance abnormal Hyperammonemia Aluminium abnormal NOS |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Acid base balance abnormal | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Aluminium abnormal NOS | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Blood urea nitrogen increased | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Embolism pulmonary | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Hyperammonemia | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Thrombosis | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
Vein disorder NOS | Disc. AE | 22 mg/g aminoacid 1 times / day multiple, intravenous (total daily dose) Recommended Dose: 22 mg/g aminoacid, 1 times / day Route: intravenous Route: multiple Dose: 22 mg/g aminoacid, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Parenteral nutrition Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of inhibitory effects of zinc and cadmium ions on agonist binding to adenosine A1 receptors in rat brain. | 1999 Aug 15 |
|
The effect of cysteine on the altered expression of class alpha and mu glutathione S-transferase genes in the rat liver during protein-calorie malnutrition. | 2000 Oct 18 |
|
Use of proteasome inhibitors to examine processing of antigens for major histocompatibility complex class I presentation. | 2001 |
|
The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions. | 2001 Feb 16 |
|
DsbD-catalyzed transport of electrons across the membrane of Escherichia coli. | 2001 Feb 2 |
|
Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). | 2001 Feb 23 |
|
Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. | 2001 Feb 23 |
|
Newly synthesized human delta opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. | 2001 Feb 9 |
|
Insect immunity. Constitutive expression of a cysteine-rich antifungal and a linear antibacterial peptide in a termite insect. | 2001 Feb 9 |
|
Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. | 2001 Jan |
|
Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. | 2001 Jan 1 |
|
Cloning and functional expression of a degradation-resistant novel isoform of p27Kip1. | 2001 Jan 1 |
|
Crystal structure of an enzyme-substrate complex provides insight into the interaction between human arylsulfatase A and its substrates during catalysis. | 2001 Jan 12 |
|
The molecular mechanism of lead inhibition of human porphobilinogen synthase. | 2001 Jan 12 |
|
The human homolog of Saccharomyces cerevisiae Apg7p is a Protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3. | 2001 Jan 19 |
|
Tigerinins: novel antimicrobial peptides from the Indian frog Rana tigerina. | 2001 Jan 26 |
|
Structural requirements for the stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin. | 2001 Jan 26 |
|
Helix packing of functionally important regions of the cardiac Na(+)-Ca(2+) exchanger. | 2001 Jan 5 |
|
The proteasome regulates receptor-mediated endocytosis of interleukin-2. | 2001 Jan 5 |
|
African swine fever virus protease, a new viral member of the SUMO-1-specific protease family. | 2001 Jan 5 |
|
Reconstitution of pterin-free inducible nitric-oxide synthase. | 2001 Jan 5 |
|
Visualization of synaptic markers in the optic neuropils of Drosophila using a new constrained deconvolution method. | 2001 Jan 8 |
|
T-cell antigen receptors in Atlantic cod (Gadus morhua l.): structure, organisation and expression of TCR alpha and beta genes. | 2001 Mar |
|
Agonistic induction of a covalent dimer in a mutant of natriuretic peptide receptor-A documents a juxtamembrane interaction that accompanies receptor activation. | 2001 Mar 16 |
|
Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S. Contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family. | 2001 Mar 16 |
|
Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens. | 2001 Mar 30 |
|
Different metabolizing ability of thiol reactants in human and rat blood: biochemical and pharmacological implications. | 2001 Mar 9 |
|
Redox properties and coordination structure of the heme in the co-sensing transcriptional activator CooA. | 2001 Mar 9 |
|
Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. | 2001 Mar 9 |
|
Rare somatic p53 mutation identified in breast cancer: a case report. | 2001 Mar-Apr |
Sample Use Guides
Cysteine Hydrochloride Injection, USP 0.5 gram is intended for use only after dilution in Aminosyn (a crystalline amino acid solution). Each 10 mL of Cysteine Hydrochloride Injection, USP 0.5 gram should be combined aseptically with 12.5 grams of amino acids, such as that present in 250 mL of Aminosyn 5%. The admixture is then diluted with 250 mL of dextrose 50% or such lesser volume as indicated. Equal volumes of Aminosyn 5% and dextrose 50% produce a final solution which contains Aminosyn 2.5% in dextrose 25%, which is suitable for administration by central venous infusion. Administration of the final admixture should begin within one hour of mixing due to the oxidative degradation of cysteine in the higher pH environment of the amino acid and dextrose admixture. Otherwise, the admixture should be refrigerated immediately and used within 12 hours of the time of mixing.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27610031
N-acetyl-L-cysteine (NAC) (1 µM ~ 1 mM) and cysteine (10 µM ~ 1 mM) increased [Ca(2+)]i in human neutrophils in a concentration-dependent manner. In Ca(2+)-free buffer, NAC- and cysteine-induced [Ca(2+)]i increase in human neutrophils completely disappeared, suggesting that NAC- and cysteine-mediated increase in [Ca(2+)]i in human neutrophils occur through Ca(2+) influx. NAC- and cysteine-induced [Ca(2+)]i increase was effectively inhibited by calcium channel inhibitors SKF96365 (10 µM) and ruthenium red (20 µM). In Na(+)-free HEPES, both NAC and cysteine induced a marked increase in [Ca(2+)]i in human neutrophils, arguing against the possibility that Na(+)-dependent intracellular uptake of NAC and cysteine is necessary for their [Ca(2+)]i increasing activity. The results show that NAC and cysteine induce [Ca(2+)]i increase through Ca(2+) influx in human neutrophils via SKF96365- and ruthenium red-dependent way.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
2180-8
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
DSLD |
1135 (Number of products:91)
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
38484-2
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
25892-1
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
FDA ORPHAN DRUG |
79693
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
JECFA EVALUATION |
L-CYSTEINE
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
15139-9
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
DSLD |
2404 (Number of products:441)
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
34277-4
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
NCI_THESAURUS |
C29596
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
20641-7
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
25891-3
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
25893-9
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
LOINC |
15133-2
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
||
|
CFR |
21 CFR 184.1271
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
17561
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
2109
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
200-158-2
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
CYSTEINE
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
35235
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
K848JZ4886
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
C29609
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
100000083990
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
15356
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
8746
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
m4048
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
5862
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
DB00151
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL863
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
29950
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
SUB23325
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
D003545
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
1409
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
K848JZ4886
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
52-90-4
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
3024
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID8022876
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
769
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
SUB06879MIG
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY | |||
|
6162
Created by
admin on Fri Dec 15 16:18:33 UTC 2023 , Edited by admin on Fri Dec 15 16:18:33 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)